Picture loading failed.

Anti-GUCY2C therapeutic antibody (Pre-made Indusatumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate that is under development for the treatment of pancreatic cancer and other gastrointestinal cancers. It consists of a monoclonal antibody (indusatumab) that targets the enzyme guanylate cyclase 2C which is present in some cancers, linked to an average of three to four molecules of the chemotherapeutic agent monomethyl auristatin E (MMAE).

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-272-1mg 1mg Inquiry
GMP-Bios-ab-272-10mg 10mg Inquiry
GMP-Bios-ab-272-100mg 100mg Inquiry
GMP-Bios-ab-272-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-GUCY2C therapeutic antibody (Pre-made Indusatumab biosimilar,Whole mAb ADC)
INN Name Indusatumab
FormatWhole mAb ADC
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesMillennium;Takeda Oncology
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedColorectal cancer;Gastrointestinal cancer;Pancreatic cancer
Development Techna